Results 171 to 180 of about 411,749 (186)

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Diabetologia, 2008
Philip D Home, G Schernthaner
exaly  

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial*

Pediatric Diabetes, 2008
Olga Kordonouri, Thomas Danne, Nicolin Datz   +2 more
exaly  

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

Diabetes, Obesity and Metabolism, 2005
P Vague, I de Leeuw, J W F Elte
exaly  

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

Diabetes, Obesity and Metabolism, 2010
Stephan D Bouman, Jeppe Sturis, Peter Kurtzhals   +2 more
exaly  

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes

Diabetes Care, 2011
Margot Umpleby, David Russell-Jones, Nicola C Jackson   +2 more
exaly  

Insulin Detemir Use Is Associated With Higher Occurrence of Hypoglycemia in Hospitalized Patients With Hypoalbuminemia

Diabetes Care, 2018
Irit Hochberg
exaly  

Insulin detemir

Reactions Weekly, 2008
openaire   +1 more source

Insulin detemir/insulin lispro

Reactions Weekly, 2007
openaire   +1 more source

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients—The PREDICTIVE™ BMI clinical trial1

Diabetic Medicine, 2008
exaly  

Insulin aspart/insulin detemir

Reactions Weekly, 2017
openaire   +1 more source